Adynxx (FRA:HL1C) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Inventories, Inventories Adjustments?

Adynxx's Inventories, Inventories Adjustments for the quarter that ended in Sep. 2019 was €0.00 Mil.

Adynxx's annual Inventories, Inventories Adjustments declined from Dec. 2016 (€0.00 Mil) to Dec. 2017 (€-0.00 Mil) but then increased from Dec. 2017 (€-0.00 Mil) to Dec. 2018 (€0.00 Mil).

Adynxx Inventories, Inventories Adjustments Historical Data

The historical data trend for Adynxx's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Inventories, Inventories Adjustments Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

-0.05

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Inventories, Inventories Adjustments	Get a 7-Day Free Trial															-	-	-	-	-

Adynxx Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines